Bombesin-like peptide mediates lung injury in a baboon model of bronchopulmonary dysplasia
View abstract on PubMed
Summary
This summary is machine-generated.Bombesin-like peptide (BLP) may drive bronchopulmonary dysplasia (BPD) in premature infants. Blocking BLP postnatally showed promise in preventing chronic lung disease in a baboon model.
Area Of Science
- Neonatal Medicine
- Pulmonary Biology
- Pediatric Respiratory Research
Background
- Bronchopulmonary dysplasia (BPD) is a chronic lung disease affecting infants surviving respiratory distress syndrome, particularly premature infants.
- The exact causes of BPD remain unclear, but increased pulmonary neuroendocrine cells containing bombesin-like peptide (BLP) are observed in affected infants.
Purpose Of The Study
- To investigate the role of BLP in mediating BPD.
- To evaluate BLP as a potential biomarker and therapeutic target for BPD.
Main Methods
- Utilized a hyperoxic baboon model to study BPD development.
- Measured urine BLP levels in response to hyperoxia and correlated them with disease severity.
- Administered anti-BLP antibody postnatally to assess its effect on BPD.
Main Results
- Elevated urine BLP levels were observed in hyperoxia-exposed baboons that developed BPD, correlating with disease severity.
- Similar BLP elevations were found in an interrupted gestation baboon model of BPD.
- Postnatal anti-BLP antibody treatment reduced clinical and pathological signs of chronic lung disease.
Conclusions
- BLP may play a mediating role in the development of BPD.
- Urine BLP levels could serve as a predictive biomarker for infants at risk of BPD.
- Targeting BLP postnatally may offer a strategy for BPD prevention.